Richard P. Baum
One of the pioneers of peptide receptor radionuclide therapy for neuroendocrine tumours, now practising at the Curanosticum theranostics centre in Wiesbaden.
Overview
Richard Baum is a specialist in nuclear medicine whom Curanosticum describes as one of the leading experts in therapeutic nuclear medicine and part of its medical team since 2020. The centre offers PET-CT, radioiodine therapy, PSMA radioligand therapy and DOTATOC receptor radionuclide therapy. Before Wiesbaden he built the theranostics programme at the Zentralklinik Bad Berka, where lutetium-177 and yttrium-90 labelled somatostatin analogues were used to treat thousands of patients with neuroendocrine tumours, work that preceded the approvals of lutetium-177 dotatate and lutetium-177 PSMA-617. His publications are listed on PubMed.
Similar pages
not linked directly; found by shared links- PersonEbrahim S. Delpassand
Shares PSMA PET, Radioligand therapy (beta emitters) and the tag leadership.
- PersonKaren E. Knudsen
Shares Prostate cancer and the tag leadership.
- PersonPaola Anna Erba
Shares Neuroendocrine tumours, Prostate cancer and the tag leadership.
- PersonAndrew Little
Shares Prostate cancer and the tag leadership.
- PersonThomas A. Hope
Shares PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonSamantha Oakes
Shares Prostate cancer and the tag leadership.
- PersonWilliam G. Nelson
Shares Prostate cancer and the tag leadership.
- CompanyPOINT Biopharma
Shares Radioligand therapy (beta emitters), Neuroendocrine tumours, Prostate cancer.